Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease.

"Declarations Ethics approval and consent to participateEthics approval and consent to participate is applicable to ADNI data and available for the purpose of this study. Consent for publicationNot applicable. Competing interestsAG is a partner of Quantify Research AB, providing consultancy services to pharmaceutical companies and other private and public organizations and institutions. ML is an employee of Quantify Research AB. LLR is an employee of Eli Lilly and Company. LJ has received research funding and consultancy fees from the following pharmaceutical companies: Novo Nordisk, Eli Lilly, Eisai and Lundbeck. Competing interests AG is a partner of Quantify Research AB, providing consultancy services to pharmaceutical companies and other private and public organizations and institutions. ML is an employee of Quantify Research AB. LLR is an employee of Eli Lilly and Company. LJ has received research funding and consultancy fees from the following pharmaceutical companies: Novo Nordisk, Eli Lilly, Eisai and Lundbeck."

"Funding Open access funding provided by Karolinska Institute. Funding for medical writing services was paid to Quantify Research (Kripi Syal) for the development of this manuscript."